Latest Regulatory Filings News

Alara Resources Limited has addressed an ASX query regarding the late filing of a director's interest notice, attributing the delay to complexities in share ownership disclosure. The company confirms existing compliance arrangements remain robust.

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.

Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

Domino’s Pizza Enterprises has explained the late filing of a director interest notice as an administrative oversight, reaffirming its compliance procedures amid ASX scrutiny.

FirstWave Cloud Technology reports a slight revenue decline in Q4 FY25, offsets challenges with strategic restructuring and a new AWS marketplace partnership.

Winchester Energy has appointed Jason Peterson and David Wheeler as non-executive directors, restoring its board to the required three members and addressing recent regulatory notices.

Jameson Resources has significantly boosted the economic outlook of its Crown Mountain Hard Coking Coal Project, doubling its pre-tax NPV to US$942 million, while advancing environmental approvals and Indigenous partnerships in British Columbia.

Memphasys Limited has submitted its Felix™ sperm separation system for CE Mark approval, targeting Europe’s $5 billion IVF market, while expanding direct sales in Japan and validating its RoXsta™ oxidative stress diagnostic platform.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.

Netlinkz Limited reported $979,000 in quarterly receipts and a landmark $1 million VSN license sale in the Philippines, while advancing significant cost reductions and debt restructuring efforts.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.